4,013
Views
7
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China

, , , , , & show all
Pages 339-344 | Received 08 Oct 2020, Accepted 08 Feb 2021, Published online: 01 Mar 2021

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.